Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Segundo Mariz

Showing results (1-10 of 26) with videos related to

Pageof 3
Sort By:
Diabetes Research and Clinical Practice|October 21, 2006
Beta-cell preservation with thiazolidinedionesIan W Campbell, Segundo Mariz
BMJ (Clinical Research Ed.)|January 13, 2011
Orphan drugs. EU regulationsSegundo Mariz, Jordi Llinares, Kerstin Westermark
International Journal of Pharmaceutics|April 11, 2012
The development and registration of topical pharmaceuticalsChristopher J Mugglestone, Segundo Mariz, Majella E Lane
Diabetes & Vascular Disease Research|October 2, 2007
Long-term effects of pioglitazone versus gliclazide on hepatic and humoral coagulation factors in patients with type 2 diabetesGabriele Perriello, Simone Pampanelli, Paolo Brunetti, et al.
Orphanet Journal of Rare Diseases|January 23, 2017
Evolving prevalence of haematological malignancies in orphan designation procedures in the European UnionBenedetta Polsinelli, Stelios Tsigkos, Frauke Naumann-Winter, et al.
Pharmacoeconomics|December 29, 2006
A lifetime modelled economic evaluation comparing pioglitazone and rosiglitazone for the treatment of type 2 diabetes mellitus in the UKDominic P Tilden, Segundo Mariz, Gillies O'Bryan-Tear, et al.
Nature Reviews. Drug Discovery|June 2, 2016
Regulatory watch: The orphan drug pipeline in EuropeThomas Morel, André Lhoir, Eline Picavet, et al.
Frontiers in Medicine|July 12, 2021
Regulatory Standards in Orphan Medicinal Product Designation in the EUStelios Tsigkos, Segundo Mariz, Maria Elzbieta Sheean, et al.
British Journal of Clinical Pharmacology|March 27, 2021
Haemophilia, state of the art and new therapeutic opportunities, a regulatory perspectiveFrancesca Tomeo, Segundo Mariz, Angelo Loris Brunetta, et al.
Frontiers in Medicine|June 1, 2017
Advanced Therapy Medicinal Products for Rare Diseases: State of Play of Incentives Supporting Development in EuropeAndreas M Farkas, Segundo Mariz, Violeta Stoyanova-Beninska, et al.
Pageof 3

Showing results (1-10 of 26) with videos related to

Sort By:
Pageof 3
Diabetes Research and Clinical Practice|October 21, 2006
Beta-cell preservation with thiazolidinedionesIan W Campbell, Segundo Mariz
BMJ (Clinical Research Ed.)|January 13, 2011
Orphan drugs. EU regulationsSegundo Mariz, Jordi Llinares, Kerstin Westermark
International Journal of Pharmaceutics|April 11, 2012
The development and registration of topical pharmaceuticalsChristopher J Mugglestone, Segundo Mariz, Majella E Lane
Diabetes & Vascular Disease Research|October 2, 2007
Long-term effects of pioglitazone versus gliclazide on hepatic and humoral coagulation factors in patients with type 2 diabetesGabriele Perriello, Simone Pampanelli, Paolo Brunetti, et al.
Orphanet Journal of Rare Diseases|January 23, 2017
Evolving prevalence of haematological malignancies in orphan designation procedures in the European UnionBenedetta Polsinelli, Stelios Tsigkos, Frauke Naumann-Winter, et al.
Pharmacoeconomics|December 29, 2006
A lifetime modelled economic evaluation comparing pioglitazone and rosiglitazone for the treatment of type 2 diabetes mellitus in the UKDominic P Tilden, Segundo Mariz, Gillies O'Bryan-Tear, et al.
Nature Reviews. Drug Discovery|June 2, 2016
Regulatory watch: The orphan drug pipeline in EuropeThomas Morel, André Lhoir, Eline Picavet, et al.
Frontiers in Medicine|July 12, 2021
Regulatory Standards in Orphan Medicinal Product Designation in the EUStelios Tsigkos, Segundo Mariz, Maria Elzbieta Sheean, et al.
British Journal of Clinical Pharmacology|March 27, 2021
Haemophilia, state of the art and new therapeutic opportunities, a regulatory perspectiveFrancesca Tomeo, Segundo Mariz, Angelo Loris Brunetta, et al.
Frontiers in Medicine|June 1, 2017
Advanced Therapy Medicinal Products for Rare Diseases: State of Play of Incentives Supporting Development in EuropeAndreas M Farkas, Segundo Mariz, Violeta Stoyanova-Beninska, et al.
Pageof 3